Puramed Bioscience Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues
Puramed Bioscience Inc. reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues of $1.49 million for the 12-month period ending 2014-06-30, per its 10-K filed 2014-10-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues · last filed 2014-10-14
- Puramed Bioscience Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for fiscal 2014 was $1.49M, a 300.81% increase from fiscal 2013.
- Puramed Bioscience Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for fiscal 2013 was $371.50K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues 12 month |
|---|---|
| 2014-06-30 | $1.49M 10-K · filed 2014-10-14 |
| 2013-06-30 | $371.50K 10-K · filed 2014-10-14 |